Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers
暂无分享,去创建一个
D. Fliser | R. Agrawal | H. Haller | F. Bahlmann | M. Meier | C. Lindschau | S. Bode-Böger | Joon-Keun Park | J. Kielstein | J. Menne | T. Kirsch | A. Marx | Dominik Midler
[1] J. Lim,et al. VCAM-1 upregulation via PKCδ-p38 kinase-linked cascade mediates the TNF-α-induced leukocyte adhesion and emigration in the lung airway epithelium , 2005 .
[2] H. Haller,et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. , 2004, Diabetes.
[3] R. Strieter,et al. Interleukin-7 and Transforming Growth Factor-β Play Counter-regulatory Roles in Protein Kinase C-δ-dependent Control of Fibroblast Collagen Synthesis in Pulmonary Fibrosis* , 2004, Journal of Biological Chemistry.
[4] J. Cooke. Asymmetrical Dimethylarginine: The Über Marker? , 2004, Circulation.
[5] T. Hewett,et al. PKC-α regulates cardiac contractility and propensity toward heart failure , 2004, Nature Medicine.
[6] D. Tsikas,et al. Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans , 2004, Circulation.
[7] S. Bode-Böger,et al. Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[8] P. Tsao,et al. Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence , 2003, Circulation.
[9] R. Berkels,et al. Vascular Protective Effects of Dihydropyridine Calcium Antagonists , 2003, Pharmacology.
[10] L. Ghiadoni,et al. Calcium Antagonist Treatment by Lercanidipine Prevents Hyperpolarization in Essential Hypertension , 2003, Hypertension.
[11] P. Vallance,et al. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[12] W. Kolch,et al. Induction of Apoptosis by Protein Kinase Cδ Is Independent of Its Kinase Activity* , 2002, The Journal of Biological Chemistry.
[13] T. Lehtimäki,et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine , 2001, The Lancet.
[14] C. Zoccali,et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.
[15] Jun-Hyun Yoo,et al. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. , 2001, Atherosclerosis.
[16] L. Platanias,et al. Protein Kinase C-δ Regulates Thrombin-Induced ICAM-1 Gene Expression in Endothelial Cells via Activation of p38 Mitogen-Activated Protein Kinase , 2001, Molecular and Cellular Biology.
[17] G. Jerums,et al. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. , 2001, Clinical science.
[18] G. Váradi,et al. A Ca2+-Dependent Transgenic Model of Cardiac Hypertrophy: A Role for Protein Kinase C&agr; , 2001 .
[19] F. Amenta,et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. , 2000, The Journal of pharmacology and experimental therapeutics.
[20] M. Gollasch,et al. Protein kinase Cα targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca2+]i , 2000 .
[21] D. Ganten,et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. , 2000, Hypertension.
[22] G. Gaviraghi,et al. Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. , 1999, Journal of hypertension.
[23] H. Fukui,et al. [Identification of PKC isozymes and effect of knockdown of PKC alpha by antisense oligodeoxynucleotide on iNOS expression via interleukin-1 receptor in vascular smooth muscle cells]. , 1999, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
[24] G. Oriji. Angiotensin II-induced ET and PGI2release in rat aortic endothelial cells is meditated by PKC , 1999 .
[25] F. Luft,et al. Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. , 1999, Circulation.
[26] S. Bode-Böger,et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. , 1999, Journal of the American Society of Nephrology : JASN.
[27] F. Ruschitzka,et al. A rationale for treatment of endothelial dysfunction in hypertension. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[28] P. Tsao,et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. , 1998, Circulation.
[29] M. Drab,et al. Endothelial-cell permeability and protein kinase C in pre-eclampsia , 1998, The Lancet.
[30] R. Dietz,et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. , 1997, Circulation research.
[31] E. Ritz,et al. Inhibitory effect of calcium channel blockers on human mesangial cell growth: evidence for actions independent of L-type Ca2+ channels. , 1996, Kidney international.
[32] S. Klahr,et al. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. , 1995, Kidney international.
[33] F. Luft,et al. Nuclear calcium signaling is initiated by cytosolic calcium surges in vascular smooth muscle cells. , 1994, Kidney international.
[34] F. Luft,et al. Platelet-derived growth factor and angiotensin II induce different spatial distribution of protein kinase C-alpha and -beta in vascular smooth muscle cells. , 1994, Hypertension.
[35] Hermann Hailer. Calcium antagonists and cellular mechanisms of glomerulosclerosis and atherosclerosis. , 1993 .
[36] Y. Nishizuka. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. , 1992, Science.
[37] R. Alexander,et al. Angiotensin II-stimulated Na+/H+ exchange in cultured vascular smooth muscle cells. Evidence for protein kinase C-dependent and -independent pathways. , 1987, The Journal of biological chemistry.
[38] J. Lim,et al. VCAM-1 upregulation via PKCdelta-p38 kinase-linked cascade mediates the TNF-alpha-induced leukocyte adhesion and emigration in the lung airway epithelium. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[39] T. Hewett,et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. , 2004, Nature medicine.
[40] J. Dernedde,et al. The interaction of protein kinase C isozymes alpha, iota, and theta with the cytoplasmic domain of L-selectin is modulated by phosphorylation of the receptor. , 2004, The Journal of biological chemistry.
[41] R. Strieter,et al. Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis. , 2004, The Journal of biological chemistry.
[42] W. Kolch,et al. Induction of apoptosis by protein kinase C delta is independent of its kinase activity. , 2002, The Journal of biological chemistry.
[43] L. Platanias,et al. Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. , 2001, Molecular and cellular biology.
[44] G. Váradi,et al. A Ca(2+)-dependent transgenic model of cardiac hypertrophy: A role for protein kinase Calpha. , 2001, Circulation.
[45] M. Gollasch,et al. Protein kinase calpha targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca(2+)](i). , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] G. Oriji. Angiotensin II-induced ET and PGI2 release in rat aortic endothelial cells is mediated by PKC. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.
[47] D. Ganten,et al. Hypertension-induced end-organ damage : A new transgenic approach to an old problem. , 1999, Hypertension.
[48] J. Ménard,et al. High human renin hypertension in transgenic rats. , 1997, Hypertension.
[49] K. Hilgers,et al. Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. , 1996, Kidney & blood pressure research.
[50] C. Garrote,et al. [Calcium antagonists]. , 1995, Enfermeria intensiva.
[51] H. Haller. Calcium antagonists and cellular mechanisms of glomerulosclerosis and atherosclerosis. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[52] M. J. Holtzman,et al. Interferon- (cid:1) -induced Epithelial ICAM-1 Expression and Monocyte Adhesion INVOLVEMENT OF PROTEIN KINASE C-DEPENDENT c-Src TYROSINE KINASE ACTIVATION PATHWAY* , 2022 .
[53] G. Dorn,et al. Protein Kinase C (cid:1) Negatively Regulates Systolic and Diastolic Function in Pathological Hypertrophy , 2022 .